ClinicalTrials.gg
WithdrawnNCT04696601OLFASCANUpdated Feb 7, 2024

Rapid Screening for Olfactory Disorders in Covid-19 Infection

An interventional study of Olfactory test in Olfaction Disorders and COVID-19 Testing, sponsored by Centre Hospitalier Universitaire de Nice. Withdrawn at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Screening

Why this study was withdrawn
Because of logistical problems
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Loss of smell is very frequently found in Europe during Covid-19 attack. This symptom was not initially expected as part of the classic symptomatology. This loss of smell mainly concerns patients with few or no symptoms, without criteria of severity and usually treated on an outpatient basis. As a result, given the unexpected occurrence of this symptom (with less awareness in the general and medical population) and the potential risk of contamination of Covid+ and anosmic subjects (due to their less symptomatic form), it is interesting to be able to propose large-scale screening for loss of sense of smell in order to preferentially direct subjects diagnosed as anosmic towards RT-PCR-type screening. In the medium term, the loss of smell seems to persist after the infectious phase, with delayed or persistent recovery, which can lead to negative psychological repercussions.

The objective is to propose large-scale screening of the general population for loss of sense of smell during a pandemic period, in order to facilitate diagnostic orientation of the population. The diagnosis of loss of smell will be carried out using a simple olfactory test in the form of an olfactory stick to be smelled.

02

Conditions studied

  • Olfaction Disorders
  • COVID-19 Testing

Keywords

  • Olfaction Disorders
  • Hyposmia
  • Dysosmia
  • Anosmia
  • Covid-19
03

In context

Olfaction Disorders

70 studies on the registry are indexed under Olfaction Disorders; 18 are open to participants now.

Browse Olfaction Disorders studies →

Lead sponsor

Centre Hospitalier Universitaire de Nice is the lead sponsor of 723 studies on the registry; 176 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject presenting himself at the covid-19 screening centre set up by the city of Nice

Exclusion criteria

Exclusion Criteria:

  • Presence of a sensory deficit (auditory or visual) preventing the subject from answering the questions perfectly during the olfactory test.
  • Subject receiving cancer chemotherapy
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Olfactory test

    The result of the olfactory test will be compared to the result of the RT-PCR test.

    Diagnostic Test: Olfactory test

Interventions

  • Diagnostic testOlfactory test

    The olfactory test (Olfascan) is in the form of a paper stick, previously impregnated with an odorant (non-liquid). It is placed a few centimetres from the participant's nose at the time of the test. It is a single-use test, without contact with the participant.

06

What researchers measure

Primary outcomes

  1. Olfactory test

    Sensitivity of the olfactory test (Olfascan) for measuring anosmia, compared to the reference diagnostic test (RT-PCR analysis).

    Time frame: Day 0

07

Study locations

1 site
  • CHU de Nice
    Nice, 06003, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Jan 2023, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2020
First posted
Jan 6, 2021
StartActual
Jan 8, 2021
Primary completionActual
Jan 1, 2023
CompletionActual
Jan 1, 2023
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04696601
Responsible party
Sponsor
First posted
Jan 6, 2021
Start date
Jan 8, 2021
Primary completion
Jan 1, 2023
Completion
Jan 1, 2023
Last update
Feb 7, 2024

Study contacts

Renaud DAVID, Dr
principal investigator · Centre Hospitalier Universitaire de Nice

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion